tradingkey.logo
tradingkey.logo
Suchen

Bone Biologics Corp

BBLG
Zur Watchlist hinzufügen
1.420USD
+0.020+1.43%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
2.55MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Bone Biologics Corp Unternehmen

Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Bone Biologics Corp Informationen

BörsenkürzelBBLG
Name des UnternehmensBone Biologics Corp
IPO-datumNov 27, 2015
CEOFrelick (Jeffrey)
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeNov 27
Addresse2 Burlington Woods Dr Ste 100
StadtBURLINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01803-4551
Telefon17815524452
Websitehttps://www.bonebiologics.com/
BörsenkürzelBBLG
IPO-datumNov 27, 2015
CEOFrelick (Jeffrey)

Führungskräfte von Bone Biologics Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
359.00
+0.84%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
359.00
+0.84%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Bone Biologics Corp?

Die fünf größten Anteilseigner von Bone Biologics Corp sind: Mr. Jeffrey Frelick

Wie viele Institutionen halten Anteile an Bone Biologics Corp (BBLG)?

Mit Stand vom 2026Q1 halten 17 Institutionen Anteile an Bone Biologics Corp, mit einem Gesamtmarktwert von etwa 58.41K, was 3.25% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 22009.00 gestiegen.